State-by-State: Where 503A Compounding Still Protects Your GLP-1 Access

Geographic guide to 503A compounding access after the 503B ban.

The Context

The FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List has sent shockwaves through the compounded GLP-1 industry. With the public comment period closing June 29, the timeline for a final rule is Q3–Q4 2026. This article examines one critical dimension of that transition.

What You Need to Know

The compounding landscape for GLP-1 medications is changing permanently. Since the shortage era began in 2022, compounded semaglutide and tirzepatide have served millions of patients who couldn't access or afford brand-name medications priced at $1,000+ per month. That access pathway is narrowing.

503A patient-specific compounding remains legal and will continue regardless of the 503B decision. Brand-name manufacturers have introduced savings programs bringing costs down significantly from list price. New oral formulations — including oral Wegovy (launched January 2026) and pipeline drugs like elecoglipron (SOLSTICE trial published in The Lancet, June 2026) — are expanding format options beyond injectable-only.

The patients most affected are those without insurance coverage, without access to manufacturer savings programs, and in geographic areas with limited 503A compounding pharmacy infrastructure. For these patients, the 503B exclusion represents a genuine access crisis that the FDA's "clinical need" framework doesn't address.

The Practical Path Forward

Regardless of regulatory outcomes, patients on compounded GLP-1 medications should take three steps now. First, confirm whether your pharmacy is 503A or 503B — this determines whether your specific supply chain is affected. Second, research brand-name pricing through NovoCare (Wegovy) and LillyDirect (Zepbound) to understand your fallback options. Third, explore providers that maintain both compounded and brand-name prescribing capability for maximum flexibility.

The June 2026 research landscape also brings encouraging news beyond the regulatory situation. ENDO 2026 confirmed that GLP-1 medications improve testosterone and fertility in men with obesity. UC San Diego published the first RCT evidence of biological aging reversal with semaglutide. Large observational studies linked GLP-1 use to 50%+ reductions in obesity-related cancer risk. These findings strengthen the case for long-term GLP-1 treatment — making continued access even more important.

Providers Worth Considering